Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China · Delayed Price · Currency is CNY 21.23
-0.80 (-3.63%)
At close: Sep 10, 2026
Enwei Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,163 | 2,672 | 2,307 | 2,911 | 2,789 | - | |
Market Cap Growth | -38.00% | 15.83% | -20.75% | 4.40% | - | - |
Enterprise Value | 1,891 | 2,340 | 2,014 | 2,403 | 2,225 | - |
Last Close Price | 21.23 | 25.47 | 22.10 | 26.32 | 24.28 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 74.97 | 51.45 | 61.53 | 33.73 | 41.13 | - |
PS Ratio | 2.62 | 2.97 | 2.84 | 3.71 | 4.03 | - |
PB Ratio | 2.12 | 2.49 | 2.18 | 2.64 | 2.42 | - |
P/TBV Ratio | 2.66 | 3.13 | 2.80 | 3.41 | 2.76 | - |
P/FCF Ratio | 42.69 | 50.22 | 80.43 | - | 71.88 | - |
P/OCF Ratio | 21.53 | 24.39 | 29.24 | 34.66 | 44.72 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.29 | 2.60 | 2.48 | 3.06 | 3.22 | - |
EV/EBITDA Ratio | 24.12 | 22.25 | 23.09 | 20.87 | 22.42 | - |
EV/EBIT Ratio | 65.15 | 39.65 | 47.96 | 29.89 | 32.57 | - |
EV/FCF Ratio | 37.32 | 43.97 | 70.19 | - | 57.35 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.20 | 0.18 | 0.19 | 0.00 | - | - |
Debt / EBITDA Ratio | 2.59 | 1.77 | 2.24 | 0.01 | - | - |
Debt / FCF Ratio | 4.00 | 3.53 | 6.90 | - | - | - |
Net Debt / Equity Ratio | -0.27 | -0.32 | -0.30 | -0.35 | -0.50 | -0.12 |
Net Debt / EBITDA Ratio | -3.55 | -3.29 | -3.64 | -3.40 | -5.83 | -0.61 |
Net Debt / FCF Ratio | -5.37 | -6.49 | -11.05 | 7.83 | -14.90 | -1.59 |
Asset Turnover | 0.56 | 0.59 | 0.57 | 0.57 | 0.61 | 0.79 |
Inventory Turnover | 3.36 | 4.18 | 3.63 | 3.63 | 3.23 | 3.17 |
Quick Ratio | 3.43 | 1.86 | 3.42 | 3.16 | 3.64 | 1.38 |
Current Ratio | 4.21 | 2.14 | 3.99 | 3.75 | 4.21 | 2.08 |
Return on Equity (ROE) | 2.81% | 4.88% | 3.47% | 7.65% | 7.55% | 16.56% |
Return on Assets (ROA) | 1.23% | 2.41% | 1.85% | 3.66% | 3.75% | 7.25% |
Return on Invested Capital (ROIC) | 3.05% | 6.51% | 4.64% | 10.65% | 9.94% | 15.87% |
Return on Capital Employed (ROCE) | 2.40% | 5.40% | 3.30% | 7.10% | 5.80% | 14.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.37% | 1.94% | 1.63% | 2.96% | 2.43% | - |
FCF Yield | 2.34% | 1.99% | 1.24% | -1.72% | 1.39% | - |
Dividend Yield | 3.02% | 2.67% | 0.81% | 2.05% | 6.59% | - |
Payout Ratio | 361.13% | 40.00% | 151.90% | 130.02% | - | 45.22% |
Buyback Yield / Dilution | -4.65% | -2.06% | 1.82% | -21.93% | -8.34% | -6.51% |
Total Shareholder Return | -1.62% | 0.61% | 2.64% | -19.88% | -1.76% | -6.51% |